Fact checked by Nick Blackmer Semaglutide has been approved by the Food and Drug Administration (FDA) for type 2 diabetes ...

A new analysis estimates that losing as little as 5% weight can lead to substantial savings in health care costs elsewhere.

Data suggests that dramatic weight loss, including via GLP-1 drugs, could save Americans big bucks in healthcare spending.

With the Biden administration pushing for Medicare, Medicaid coverage of GLP-1s, analysts disagree on whether it will ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.

GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and ...

Still, some patients struggle to access the drugs due to the spotty insurance coverage of weight loss treatments in the U.S. Without insurance or other savings, Zepbound and Wegovy both cost ...